Patents by Inventor Eva Prieschl-Grassauer
Eva Prieschl-Grassauer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240252529Abstract: Sulphated polysaccharides for use as an antiviral active ingredient in an antiviral effective amount in a pharmaceutical composition or medicament for the prophylactic or therapeutic intervention of a SARS-CoV-2 infection in a human individual or non-human animal.Type: ApplicationFiled: July 9, 2021Publication date: August 1, 2024Applicant: MARINOMED BIOTECH AGInventors: Eva PRIESCHL-GRASSAUER, Andreas GRASSAUER, Martina MOROKUTTI-KURZ, Philipp GRAF
-
Patent number: 11510859Abstract: A method of increasing the solubility of a water-insoluble or slightly water-soluble hydrophobic organic compound in an aqueous solvent includes adding a saponin component selected from escin, glycyrrhizin, and Quillaya saponaria extract to the aqueous solvent in an amount sufficient to trigger the formation of micelles, wherein in a first step the hydrophobic organic compound is pre-dissolved in an organic solvent, and in a second step the organic solvent comprising the pre-dissolved compound is admixed to the aqueous solvent, whereby at least a part of the insoluble or slightly soluble hydrophobic organic compound gets solubilized and dissolved in the aqueous solvent, yielding an aqueous composition having an increased concentration of said organic compound dissolved therein. Also indicated are pharmaceutical or cosmetic compositions including a water-insoluble or slightly water-soluble organic compound dissolved in an aqueous solvent at substantially increased concentrations.Type: GrantFiled: July 15, 2016Date of Patent: November 29, 2022Assignee: MARINOMED BIOTECH AGInventors: Andreas Grassauer, Eva Prieschl-Grassauer, Angelika Bodenteich, Martina Morokutti-Kurz, Sabine Nakowitsch, Cornelia Kaintz
-
Patent number: 10660914Abstract: A pharmaceutical composition has a stuffy nose deblocking activity. The composition includes a hyperosmolar aqueous solution of a non-ionic osmolality adjusting agent, optionally in combination with an ionic osmolality adjusting agent, wherein the composition further includes iota-carrageenan and/or kappa-carrageenan as an active antiviral ingredient in an antivirally effective amount, with the proviso that the composition in its ready-for-use formulation contains no more than 0-1.5% w/v of the ionic osmolality adjusting agent. The composition is useful for deblocking a stuffy nose and for prophylactic or therapeutic intervention of a number of viral infections of the upper respiratory tract.Type: GrantFiled: July 12, 2016Date of Patent: May 26, 2020Assignee: MARINOMED BIOTECH AGInventors: Andreas Grassauer, Eva Prieschl-Grassauer, Angelika Bodenteich, Christiane Koller, Martina Morokutti-Kurz
-
Patent number: 10376537Abstract: Disclosed herein is a method of reducing the risk of a rhinovirus infection, the method includes administering to a subject a composition comprising iota-carrageenan in an antiviral effective amount as an active antiviral ingredient.Type: GrantFiled: August 23, 2012Date of Patent: August 13, 2019Assignee: MARINOMED BIOTECH AGInventors: Andreas Grassauer, Eva Prieschl-Grassauer, Christiane Koller, Alexander Pretsch
-
Patent number: 10342820Abstract: The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus. The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus.Type: GrantFiled: May 30, 2012Date of Patent: July 9, 2019Assignee: MARINOMED BIOTECH AGInventors: Andreas Grassauer, Eva Prieschl-Grassauer
-
Patent number: 10220055Abstract: The present invention relates to a pharmaceutical composition for use as a medicament in the prophylactic or therapeutic topical treatment of viral eye infections caused by adenovirus of subtype D or influenza A virus of subtype H7. The composition in its ready-for-use formulation comprises iota carrageenan as an active antiviral ingredient and is substantially free of a metal halide salt or contains no more than 0.5% w/v of a metal halide salt.Type: GrantFiled: January 20, 2015Date of Patent: March 5, 2019Assignee: NICOX S.A.Inventors: Eva Prieschl-Grassauer, Martina Morokutti-Kurz, Andreas Grassauer, Sabine Nakowitsch, Angelika Bodenteich, Marielle König-Schuster, Christiane Koller, Frederic Pilotaz
-
Publication number: 20190060202Abstract: A method of increasing the solubility of a water-insoluble or slightly water-soluble hydrophobic organic compound in an aqueous solvent includes adding a saponin component selected from escin, glycyrrhizin, and Quillaya saponaria extract to the aqueous solvent in an amount sufficient to trigger the formation of micelles, wherein in a first step the hydrophobic organic compound is pre-dissolved in an organic solvent, and in a second step the organic solvent comprising the pre-dissolved compound is admixed to the aqueous solvent, whereby at least a part of the insoluble or slightly soluble hydrophobic organic compound gets solubilized and dissolved in the aqueous solvent, yielding an aqueous composition having an increased concentration of said organic compound dissolved therein. Also indicated are pharmaceutical or cosmetic compositions including a water-insoluble or slightly water-soluble organic compound dissolved in an aqueous solvent at substantially increased concentrations.Type: ApplicationFiled: July 15, 2016Publication date: February 28, 2019Applicant: MARINOMED BIOTECH AGInventors: Andreas GRASSAUER, Eva PRIESCHL-GRASSAUER, Angelika BODENTEICH, Martina MOROKUTTI-KURZ, Sabine NAKOWITSCH, Cornelia KAINTZ
-
Publication number: 20190060358Abstract: A pharmaceutical composition has a stuffy nose deblocking activity. The composition includes a hyperosmolar aqueous solution of a non-ionic osmolality adjusting agent, optionally in combination with an ionic osmolality adjusting agent, wherein the composition further includes iota-carrageenan and/or kappa-carrageenan as an active antiviral ingredient in an antivirally effective amount, with the proviso that the composition in its ready-for-use formulation contains no more than 0-1.5% w/v of the ionic osmolality adjusting agent. The composition is useful for deblocking a stuffy nose and for prophylactic or therapeutic intervention of a number of viral infections of the upper respiratory tract.Type: ApplicationFiled: July 12, 2016Publication date: February 28, 2019Applicant: MARINOMED BIOTECH AGInventors: Andreas GRASSAUER, Eva PRIESCHL-GRASSAUER, Angelika BODENTEICH, Christiane KOLLER, Martina MOROKUTTI-KURZ
-
Patent number: 10022449Abstract: The present invention relates to iota- and/or kappa-carrageenan in combination with a neuraminidase inhibitor for use as a medicament in the prophylactic or therapeutic treatment of a symptom, condition or disease caused by or associated with an infection by an influenza virus.Type: GrantFiled: December 17, 2010Date of Patent: July 17, 2018Assignee: MARINOMED BIOTECHNOLOGIE GmbHInventors: Andreas Grassauer, Eva Prieschl-Grassauer, Christiane Meier, Marielle Konig-Schuster
-
Publication number: 20160331776Abstract: The present invention relates to a pharmaceutical composition for use as a medicament in the prophylactic or therapeutic topical treatment of viral eye infections caused by adenovirus of subtype D or influenza A virus of subtype H7. The composition in its ready-for-use formulation comprises iota carrageenan as an active antiviral ingredient and is substantially free of a metal halide salt or contains no more than 0.5% w/v of a metal halide salt.Type: ApplicationFiled: January 20, 2015Publication date: November 17, 2016Inventors: Eva PRIESCHL-GRASSAUER, Martina MOROKUTTI-KURZ, Andreas GRASSAUER, Sabine NAKOWITSCH, Angelika BODENTEICH, Marielle KÖNIG-SCHUSTER, Christiane KOLLER, Frederic PILOTAZ
-
Publication number: 20120315311Abstract: Disclosed herein is a method of reducing the risk of a rhinovirus infection, the method includes administering to a subject a composition comprising iota-carrageenan in an antiviral effective amount as an active antiviral ingredient.Type: ApplicationFiled: August 23, 2012Publication date: December 13, 2012Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas GRASSAUER, Eva PRIESCHL-GRASSAUER, Christiane MEIER, Alexander PRETSCH
-
Publication number: 20120302522Abstract: The present invention relates to iota- and/or kappa-carrageenan in combination with a neuraminidase inhibitor for use as a medicament in the prophylactic or therapeutic treatment of a symptom, condition or disease caused by or associated with an infection by an influenza virus.Type: ApplicationFiled: December 17, 2010Publication date: November 29, 2012Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas Grassauer, Eva Prieschl-Grassauer, Christiane Meier, Marielle Konig-Schuster
-
Patent number: 8282969Abstract: A method for manufacturing an antiviral pharmaceutical composition for the prophylaxis or treatment of a rhinovirus infection that includes the utilization of iota-, kappa- or lambda-carrageenan or mixtures thereof.Type: GrantFiled: December 4, 2007Date of Patent: October 9, 2012Assignee: Marinomed Biotechnologie GmbHInventors: Andreas Grassauer, Eva Prieschl-Grassauer, Christiane Koller, Alexander Pretsch
-
Publication number: 20120237572Abstract: The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus, The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus.Type: ApplicationFiled: May 30, 2012Publication date: September 20, 2012Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas GRASSAUER, Eva PRIESCHL-GRASSAUER
-
Publication number: 20120058206Abstract: The present invention relates to pharmaceutical compositions for administration to the respiratory tract, the gastrointestinal tract or the eyes. In particular, the invention relates to liquid formulations and dry powder compositions comprising carrageenan, and in particular iota and kappa carrageenan, and one or more therapeutic agents. These sprays, powders, and the gel that forms when they are administered to the respiratory tract, the gastrointestinal tract or the eyes, have now surprisingly been found to be a very effective way of prevention and treatment of type I allergies and intranasal administration of therapeutic agents.Type: ApplicationFiled: September 19, 2011Publication date: March 8, 2012Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas GRASSAUER, Eva PRIESCHL-GRASSAUER
-
Publication number: 20110224160Abstract: The present invention provides the use of escin for the manufacture of a pharmaceutical preparation for the treatment of a Type IV hypersensitivity reaction or symptoms of a Type IV hypersensitivity reaction, such as in contact dermatitis, atopic dermatitis, hypersensitivity pneumonitis, chronic transplant rejection, graft versus host disease, cell mediated autoimmune diseases, Hashimoto's thyroiditis, Sjogren's disease, adrenalitis, polymyositis, or pernicious anemia.Type: ApplicationFiled: November 16, 2009Publication date: September 15, 2011Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Eva Prieschl-Grassauer, Thomas Friedrich
-
Publication number: 20110091583Abstract: The present invention relates to pharmaceutical compositions based on carrageenan as an active ingredient, for use as a medicament in the prophylactic or therapeutic treatment of allergic conditions or diseases, with the proviso that the carrageenan comprises iota- and/or kappa-carrageenan and is substantially free of lambda carrageenan. Typically, the invention relates to liquid formulations, gels and dry powder compositions comprising iota- and/or kappa-carrageenan and, optionally, one or more non-carrageenan therapeutic agents for administration to the respiratory tract, the gastrointestinal tract or the eyes. The compositions of the invention have been found to be efficacious in the prevention and treatment of type I allergies and additionally, may exert an adjuvant function upon combined mucosal administration with non-carrageenan therapeutic agents.Type: ApplicationFiled: June 30, 2009Publication date: April 21, 2011Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas Grassauer, Eva Prieschl-Grassauer
-
Publication number: 20110059919Abstract: The present invention provides for the use of iota- and/or kappa-carrageenan for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus, paramyxovirus, adenovirus and coronavirus. The present invention further provides for the use of fucoidan, in particular of high molecular weight fucoidan, for the manufacture of an antiviral pharmaceutical composition for the prophylaxis or treatment of a pathological condition or disease caused by or associated with an infection by a respiratory virus selected from the group consisting of orthomyxovirus and paramyxovirus.Type: ApplicationFiled: August 22, 2008Publication date: March 10, 2011Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas Grassauer, Eva Prieschl-Grassauer
-
Publication number: 20100040658Abstract: A method for manufacturing an antiviral pharmaceutical composition for the prophylaxis or treatment of a rhinovirus infection that includes the utilization of iota-, kappa- or lambda-carrageenan or mixtures thereof.Type: ApplicationFiled: December 4, 2007Publication date: February 18, 2010Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas Grassauer, Eva Prieschl-Grassauer, Christiane Meier, Alexander Pretsch
-
Publication number: 20080131454Abstract: The present invention provides the use of carrageenan or mixtures thereof for the manufacture of an antiviral pharmaceutical composition for the treatment of rhinovirus infections.Type: ApplicationFiled: December 5, 2006Publication date: June 5, 2008Applicant: MARINOMED BIOTECHNOLOGIE GMBHInventors: Andreas Grassauer, Eva Prieschl-Grassauer, Christiane Meier, Alexander Pretsch